Jay Wu
VM Discovery, Inc.
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Jay Wu as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 10:47 UTC. Open this list on ClinicalTrials.gov
- Ph1/Ph2NCT07636785 · A Phase 1 and 2 Study of VMD-102 in Hepatocellular Carcinoma and Other Solid TumorsVM Discovery, Inc. · recruiting · Hepatocellular Carcinoma (HCC), Metastatic Uveal Melanoma, Renal Cell Carcinoma (RCC) · study chair
Grants
NIH projects from RePORTER, fetched 2026-11-12 10:47 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 1 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Preclinical Development of Selective PKC_epsilon Inhibitors to Treat AlcoholismR44AA014843 · NIAAA · VM DISCOVERY, INC. · fiscal years 2007 to 2013 · $463,933 awarded in 2013Same name and institution; not confirmed by an ID
- TAS::75 0849::TAS DEVELOPMENT OF ANTI-CANCER AGENTS.26120100010 · NCI · VM DISCOVERY, INC. · fiscal years 2010 · $198,224 awarded in 2010Same name and institution; not confirmed by an ID
- Multi-Property Design Selective PKC_epsilon InhibitorsR43AA014843 · NIAAA · VM DISCOVERY, INC. · fiscal years 2004 · $98,153 awarded in 2004Same name and institution; not confirmed by an ID
Most cited trial papers
Clinical-trial papers with this author name in non-small cell lung cancer, ranked by citations from NIH iCite, fetched 2026-11-12 10:47 UTC. The ranking covers the 200 most relevant of 41 PubMed records, and a shared surname and initials can bring in a namesake. All 41 on PubMed
- Phase IB/II Trial of Lenvatinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma, Endometrial Cancer, and Other Selected Advanced Solid Tumors.J Clin Oncol · 2020374 citationsRCR 15.1
- 352 citationsRCR 16.2
- 213 citationsRCR 14.3
- Toripalimab Plus Chemotherapy for Patients With Treatment-Naive Advanced Non-Small-Cell Lung Cancer: A Multicenter Randomized Phase III Trial (CHOICE-01).J Clin Oncol · 2023173 citationsRCR 10.8
- Phase Ib Study of Telisotuzumab Vedotin in Combination With Erlotinib in Patients With c-Met Protein-Expressing Non-Small-Cell Lung Cancer.J Clin Oncol · 2023105 citationsRCR 8.9
- Phase I, Open-Label, Dose-Escalation/Dose-Expansion Study of Lifirafenib (BGB-283), an RAF Family Kinase Inhibitor, in Patients With Solid Tumors.J Clin Oncol · 202092 citationsRCR 3.4
- Toripalimab plus chemotherapy as second-line treatment in previously EGFR-TKI treated patients with EGFR-mutant-advanced NSCLC: a multicenter phase-II trial.Signal Transduct Target Ther · 202189 citationsRCR 3.9
- Role of anlotinib-induced CCL2 decrease in anti-angiogenesis and response prediction for nonsmall cell lung cancer therapy.Eur Respir J · 201977 citationsRCR 2.7
- Phase I Study of 2- or 3-Week Dosing of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, Monotherapy in Patients with Advanced Non-Small Cell Lung Carcinoma.Clin Cancer Res · 202172 citationsRCR 3.7
- 63 citationsRCR 4.9